Key result
Trial-defined bleeding correlates weakly with mortality and may be an invalid surrogate in CAD trials.
Why the study?
Bleeding events are frequently used as safety endpoints in antithrombotic RCTs for coronary artery disease, but whether bleeding is a valid surrogate for death remains uncertain.
Are nonfatal bleeding events a valid surrogate for mortality in trials of antithrombotic agents for coronary artery disease?
Meta-Analysis (n=181,951)
Are nonfatal bleeding events a valid surrogate for mortality in trials of antithrombotic agents for coronary artery disease?
Trial-defined bleeding events may not be valid surrogates for mortality in RCTs investigating antithrombotic agents for coronary artery disease.
Answers are grounded in this paper and cite their sources.
Bleeding events should not serve as mortality surrogates in CAD antithrombotic RCTs; challenges their use as primary endpoints in future trials.
Bleeding events are frequently applied as safety end points for randomized controlled trials (RCTs) investigating the effect of antithrombotic agents in patients with coronary artery disease. However, whether a bleeding event is a valid surrogate for death remain uncertain. This study aimed to assess the correlation between the treatment effect on bleeding events and mortality. Multiple databases were searched to identify RCTs studying antithrombotic agents for patients with coronary artery disease through August 2022. Major and minor bleeding events were defined in included trials, mostly defined with BARC (Bleeding Academic Research Consortium) or TIMI (Thrombolysis In Myocardial Infarction) criteria. Trial-level correlations between nonfatal bleeding events and mortality were assessed. We performed subgroup analyses by the definitions of bleeding (BARC vs TIMI criteria), study year, and follow-up duration. We used a cutoff with a lower limit of 95% confidence interval of R2 >0.72 as a strong correlation and with an upper limit of 95% confidence interval of R2 <0.50 as a weak correlation. A total of 48 RCTs with 181,951 participants were analyzed. Overall, trial-level R2 for major and minor bleeding were 0.09 (95% CI: 0.00-0.26) and 0.09 (95% CI: 0.00-0.27) for all-cause or cardiovascular death, respectively. When confined to major bleeding, R2 were 0.03 (95% CI: 0.00-0.13) and 0.01 (95% CI: 0.00-0.05), respectively. All of the subgroup analyses did not show any significant correlations. We demonstrated a trial-defined bleeding event may not be a valid surrogate for mortality in RCTs investigating the effect of antithrombotic agents for coronary artery disease.
No takes yet. Share an insight, caveat, or question.
Kuno et al. (2023) conducted a meta-analysis in Coronary artery disease (n=181,951). Antithrombotic agents was evaluated on Trial-level correlation (R2) between major and minor bleeding events and all-cause death (R2 0.09, 95% CI 0.00-0.26). Trial-defined bleeding events showed weak correlation with all-cause death and may not be a valid surrogate for mortality in RCTs of antithrombotic agents for CAD.
Synapse has enriched 10 related papers. Consider them for comparative context: